New immunosuppressive strategies in liver transplantation: Balancing efficacy and toxicity

Current Opinion in Organ Transplantation

Volumn 8, Issue 2, 2003, Pages 139-145

  Vilatoba, Mario ^a   Contreras, Juan L ^a   Eckhoff, Devin E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 11244314696     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/00075200-200306000-00002     Document Type: Review

References (59)

1. Starzl TE, Zinkernagel RM: Transplantation tolerance from a historical perspective. Nat Rev Immunol 2001, 1:233-239.
2. Goddard S, Adams DH: New approaches to immunosuppression in liver transplantation. J Gastroenterol Hepatol 2002, 17:116-126.
3. Levy GA: Long-term immunosuppression and drug interactions. Liver Transpl 2001, 7:S53-S59.
4. Wiesner RH, Demetris AJ, Belle SH, et al.: Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998, 28:638-645
5. Tisone G, Angelico M, Palmieri G, et al.: A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation. Transplantation 1999, 67:1308-1313.
6. Bartlett AS, Ramadas R, Furness S, et al.: The natural history of acute histologic rejection without biochemical graft dysfunction in orthotopic liver transplantation: a systematic review. Liver Transplantation 2002, 8:1147-1153.
7. Scheiner PA, Schwartz ME, Mor E, et al.: Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic transplantation. Hepatology 1995, 21:30-34.
8. Adams RW, Chapman RL, Smallwood GA: Steroid withdrawal in liver transplant recipients. Prog Transplant 2001, 11:217-223.
9. Lerut JP, Ciccarelli O, Mauel E, et al.: Adult liver transplantation and steroidazathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression-5 year results of a prospective study. Transpl Int 2001, 14:420-428.
10. Kneteman NM: Steroid-free immunosuppression: balancing efficacy and toxicity. Liver Transpl 2001, 7:698-700.
11. Pirenne J, Aerts R, Koshiba T, et al.: Standard cyclosporine A-based versus completely steroid-free FK506-based immunosuppression after liver transplantation. Transplant Proc 2001, 33:1505.
12. Ringe B, Braun F, Schutz E, et al.: A novel management strategy of steroidfree immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation 2001, 71:508-515.
13. Volpin R, Angeli P, Galioto A, et al.: Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial. Liver Transpl 2002, 8:527-534.
14. Prados E, Cuervas-Mons V, de la Mata, et al.: Outcome of autoimmune hepatitis after liver transplantation. Transplantation 1998, 66:1645-1650.
15. Trouillot TE, Shrestha R, Kam I, et al.: Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis. Liver Transplant Surg 1999;5:375.
16. Cohen SM: Current immunosuppression in liver transplantation. Am J Ther 2002, 9:119-125.
17. Fisher RA, Ham JM, Marcos A, et al.: A prospective randomized trial of mycophenolate mofetil with Neoral or tacrolimus after orthotopic liver transplantation. Transplantation 1998, 66:1616-1621.
18. Wiesner R, Rabkin J, Klintmalm G, et al.: A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001, 7:442-450.
19. Hullett DA, Geraghty JG, Stoltenberg RL, et al.: The impact of acute rejection on the development of intimal hyperplasia associated with chronic rejection. Transplantation 1996, 27:62:1842-1846.
20. Kato T, Ruiz P, DeFaria W, et al.: Mycophenolate mofetil rescue therapy in patients with chronic hepatic allograft rejection. Transplant Proc 1999, 31:396.
21. Papatheodoridis GV, O'Beirne J, Mistry P, et al.: Mycophenolate mofetil monotherapy in stable liver transplant patients cyclosporine-induced renal impairment: a preliminary report. Transplantation 1999, 68:155-157.
22. Schlitt HJ, Barkmann A, Boker KWH, et al.: Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomized controlled study. Lancet 2001, 357:587-592.
23. Stewart SF, Hudson M, Talbot D, et al.: Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001, 357:609-610.
24. Larson CP, Elwood ET, Alexander DZ, et al.: Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996, 381:434-438.
25. Neal DA, Gimson AE, Gibbs P, et al.: Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight. Liver Transpl 2001, 7:533-539.
26. Manzarbeitia C, Reich DJ, Rothstein KD, et al.: Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients. Liver Transpl 2001, 7:93-99.
27. Wiesner RH: A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998, 66:493-499.
28. O'Grady JG, Burroughs A, Hardy P, et al.: Tacrolimus versus microemulsified cyclosporin in liver transplantation: the TMC randomized controlled trial. Lancet 2002, 360:1119-1125.
29. 2). Transplantation 2002, 73:953-959.
30. Grant D, Kneteman N, Tchervenkov J, et al.: Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8). Transplantation 1999, 67:1133.
31. Levy G, Kewon P: Comparison of efficacy and toxicity in de novo liver transplant recipients treated with Neoral using C2 monitoring versus tacrolimus using Co monitoring [abstract]. 2001 A Transplant Odyssey, August 20-23, 2001, Istanbul, Turkey.
32. Abraham RT, Wiederrecht GJ: Immunopharmacology of rapamycin. Annu Rev Immunol 1996,14:483-510.
33. Groth CG, Backman L, Morales JM, et al.: Sirolimus (rapamycin) based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999, 67:1036-1042.
34. Kahan BD, for the Rapamune US Study Group: Efficacy of sirolimus compared with azathioprine for the reduction of acute renal allograft rejection. Lancet 2000, 356:194-202.
35. McAlister VC, Peltekian KM, Malatjalian DA, et al.: Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001, 7:701-708.
36. Trotter JF, Wachs M, Bak T, et al.: Liver transplantation using sirolimus and minimal corticosteroids (3 day taper). Liver Transplant 2001, 7:343-351.
37. Pridohl O, Heinemann K, Hartwig T, et al.: Low-dose immunosuppression with FK 506 and sirolimus after liver transplantation: 1-year results. Transplant Proc 2001, 33:3229-3231.
38. Heffron TG, Smallwood GA, Davis L, et al.: Sirolimus-based immunosuppressive protocol for calcineurin sparing in liver transplantation. Transplant Proc 2002, 34:1522-1523.
39. Oertel M, Sack U, Kohlhaw K, et al.: Induction therapy including antithymocyte globulin induces marked alterations in T lymphocyte subpopulations after liver transplantation: results of a long-term study. Transpl Int 2002, 15:463-471.
40. Eason JD, Loss GE, Blazek J, et al.: Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transpl 2001, 7:693-697.
41. Depper JM, Lonard WJ, Robb RJ, et al.: Blockade of the interleukin 2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. Immunology 1983, 131:690-696.
42. Vincenti F, Kirkman R, Light S, et al.: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998, 338:161-165.
43. Nashan B, Moore R, Amlot P, et al.: Randomized trial of basiliximab versus placebo for the control of acute rejection in renal allograft recipients. Lancet 1997, 350:1193-1198.
44. Calmus Y, Scheele JR, Gonzalez-Pinto I, et al.: Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002, 8:123-131.
45. Emre S, Gondolesi G, Polat K, et al.: Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2001, 7:220-225.
46. Eckhoff DE, McGuire B, Sellers M, et al.: The safety and efficacy of a twodose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation 2000, 69:1867-1872.
47. Hirose R, Roberts JP, Quan D, et al.: Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation 2000, 69:307-311.
48. Nelson DR, Soldevia-Pico C, Reed A, et al.: Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transplantation 2001,7:1064-1070.
49. Ramos HC, Reyes J, Abu-Elmagd K, et al.: Weaning of immunosuppression in long-term liver recipients. Transplantation 1995, 59:212-217.
50. Mazariegos GE, Reyes HC, Marino IR, et al.: Weaning of immunosuppression in liver recipients. Transplantation 1997, 63:243-249.
51. Devlin J, Doherty D, Thomson L, et al.: Defining the outcomes of immunosuppression withdrawal after liver transplantation. Hepatology 1998, 27:926-933.
52. Takastuki M, Uemoto S, Inomata Y, et al.: Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001, 72:449-454.
53. McCaughan GW: Withdrawal of immunosuppression in liver transplant recipients: is this as good as it gets? Liver Transpl 2002, 8:408-410.
54. Bishop GA, McCaughan GW: Immune activation is required for the induction of allograft tolerance: implication for immunosuppressive therapy. Liver Transplant 2001, 7:161-172.
55. Qian S, Lu L, Fu F, et al.: Apoptosis within spontaneously accepted mouse liver allografts. J Immunol 1997, 158:4654-4661.
56. Sharland A, Shastry S, Wang C, et al.: Kinetics of intragraft cytokine expression, cellular infiltration, and cell death in rejection of renal allografts in a rat model. Transplantation 1998, 65:1370-1377.
57. Gold R, Buttgereit F, Toyka KV: Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunologic disorders. J Neuroimmunol 2001, 117:1-8.
58. Rolles K, Davidson BR, Burroughs AK: A study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin. Transplantation 1999, 68:1195-1198.
59. Watson CJ, Friend PJ, Jamieson NV, et al.: Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999, 67:505-509.